STOCK TITAN

Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences earnings

Lifecore Biomedical (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (CDMO), has announced that it will release its financial results for the first quarter of fiscal year 2025 on Friday, October 4, 2024, before the market opens. The company will also host a webcast at 8:30 a.m. Eastern Time on the same day.

During the webcast, Lifecore's senior management team will discuss the quarterly financial results and provide an update on recent corporate developments. Investors and interested parties can access the live webcast or archived version through the Investor Events & Presentations page on Lifecore's website at https://ir.lifecore.com/events-presentations.

Loading...
Loading translation...
Argus Session date unavailable
+14.35% session move Open Argus
Details

News Market Reaction – LFCR

The recorded move for LFCR in the trading session of this news was +14.35%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

CHASKA, Minn., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the first quarter of fiscal year 2025 on Friday, October 4, 2024, prior to market open and will host a webcast at 8:30 a.m. Eastern Time. Members of Lifecore’s senior management team will discuss financial results for the first quarter and review recent corporate developments.

To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore’s website at: https://ir.lifecore.com/events-presentations.

About Lifecore Biomedical

Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Lifecore Biomedical (LFCR) report its Q1 FY2025 financial results?

Lifecore Biomedical (LFCR) will report its financial results for the first quarter of fiscal year 2025 on Friday, October 4, 2024, before the market opens.

What time is Lifecore Biomedical's (LFCR) Q1 FY2025 earnings webcast scheduled for?

Lifecore Biomedical's (LFCR) Q1 FY2025 earnings webcast is scheduled for 8:30 a.m. Eastern Time on Friday, October 4, 2024.

Where can I access Lifecore Biomedical's (LFCR) Q1 FY2025 earnings webcast?

You can access Lifecore Biomedical's (LFCR) Q1 FY2025 earnings webcast through the Investor Events & Presentations page on the company's website at https://ir.lifecore.com/events-presentations.

What will be discussed during Lifecore Biomedical's (LFCR) Q1 FY2025 earnings call?

During Lifecore Biomedical's (LFCR) Q1 FY2025 earnings call, the senior management team will discuss the quarterly financial results and review recent corporate developments.

Keep reading